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Abstract— Currently, obesity is considered an epidemic 
due to the disruptions it causes to health, highlighting the 
incensement in cardiovascular diseases associated with 
cholesterol and low-density lipoprotein (LDL) high 
concentrations. However, cholesterol is also involved in 
various metabolic and structural functions vital to human 
biology. This homeostasis can be modified by external 
factors such as medications or by internal factors such as 
diseases or metabolic changes generated by the type of 
diet at which each person is exposed.In this sense, the 
research points to the knowledge of functional foods, 
which provide beneficial health effects and prevent the 
risk of disease. It has been reported that 
hypocholesterolemic type bioactive peptides obtained by 
enzymatic hydrolysis of various seeds such as soybeans, 
rice and sunflower. A similar effect is observed with 
unsaturated fatty acids, which have antithrombotic and 
antiarrhythmic effects, prevent atherosclerosis, contribute 
to decrease blood pressure and reduce the concentration 
of triglycerides, total cholesterol and lipoproteins of very 
low-density lipoprotein (VLDL) in plasma. Therefore, 
these compounds incorporated in  foods are considered 
functional, since its bioactive potential could be used to 
prevent cardiovascular disease. 
Keywords— cholesterol, functional foods, 
hypocholesterolemic. 
I. INTRODUCTION 
Obesity is a chronic disease originated by various causes 
and with numerous complications, characterized by body 
fat excess that threatens the health of the individual. Its 
growth isconsidered a risk worldwide, an epidemic. In 
2013, the obesity in men was 36.9% and 38% in women1. 
In 2030, the number of obesity people will increase at 573 
million2. Also, obesity carries high concentrations of total 
cholesterol and of the one found in the low-density 
lipoproteins (LDL), which are strongly associated with a 
risk increment in cardiovascular diseases, for this reason a 
reduction in total cholesterol and LDL in 
hypercholesterolemic individuals reduces the incidence of 
these diseases3. 
 
II. CHOLESTEROL AND ITSMETABOLISM 
Cholesterol is involved in various metabolic and 
structural processes that are vital to human biology. Its 
homeostasis is strict and controlled differentially4. Under 
physiological conditions, the organism obtains cholesterol 
from the diet (daily intake), the absorption rate and cell 
synthesis. The average daily intake provides 300-500 mg, 
the bile of 800 to 1200 mg and the epithelium of the 
intestinal mucosa contributes with 300 mg per day. The 
average rate of absorption of cholesterol in the intestine, 
specifically in the duodenum and jejunum, individually 
varies between 30 and 70%5. At plasma level, cholesterol 
levels are regulated by the endogenous synthesis, 
secretion and catabolism of several plasma lipoproteins6. 
It is noteworthy that the liver contributes with 20% of the 
overall input of cholesterol and is the organ that maintains 
homeostasis by five mechanisms: a) By the 3-hydroxy-3-
methyl-glutaryl coenzyme A reductase (HMGCoAR); b) 
The consumption through low-density lipoprotein 
receptors (LDLr), c) The release of lipoproteins in the 
blood, d) The esterification and storage, e) The 
degradation/conversion into bile salts4,7.However, this 
homeostasis can be modified by external factors such as 
medications or by internal factors such as diseases and 
metabolic changes. 
In the enterocyte, approximately half of the cholesterol 
molecules are introduced into the endoplasmic reticulum 
(ER), where this biomolecule is esterified by the 
corresponding acyltransferase (ACAT) before its 
incorporation into the nascent 
chylomicron8.Chylomicrons release triglycerides to 
peripheral tissues by the hydrolysis of lipoprotein lipase 
(LPL) through vascular pathway and its abundant in 
cholesterol remnants are taken up by hepatocytes for the 
synthesis of bile acid or are incorporated into very low-
density lipoproteins (VLDL), which are released into the 
systemic circulation. VLDL are also assembled in the 
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liver and they distribute triglyceridesand cholesterol to 
peripheral cells, where they become LDL after partial 
depletion has occurred in triglycerides, due to vascular 
LPL activity. LDL are considered "bad" cholesterol 
because it causes the release of cholesterol in peripheral 
tissues. In contrast, high-density lipoprotein (HDL) 
contains A1 and A2 apolipoproteins(APOA1 and APO2, 
respectively), which serve as acceptors and trap 
cholesterol from peripheral tissues effectively8,9.VLDL 
are the primary cholesterol source for the peripheral 
tissues via the LDLr, which is the major regulatory step to 
adjust the importance of this biomolecule. Export from 
cells requires both the expression of ABC superfamily 
(belt conveyors coupled to ATP) and extracellular 
presence of apolipoproteins as free cholesterol acceptors. 
If cholesterol is in excess, the body accelerates its 
conversion into bile acids, allowing its elimination in the 
stool, which is the only route of excretion of this 
substance. On the other hand, if the supplement of 
cholesterol is low, the de novosynthesis iscarried out in 
the liver 3,10. 
De novo synthesis requires that genes involved in 
cholesterol productionbe transcribed, such as LDLr and 
HMGR. These genes are transcribed in terms of the 
amount of sterols detected by some cellular transcription 
factors. The cholesterol reservation obtained from de 
novo synthesis by hepatocytes will subsequently be 
esterified by ACAT and incorporated into VLDL APO B-
100, which will be secreted into blood and transported 
into tissues. Also, the peripheral tissues contribute to 
hepatic cholesterol reservation through itstransfer to the 
liver in a process mediated by HDL9. Cellular transport of 
this substance can change LDLr synthesis, which 
contributes to cell and blood cholesterol concentration. 
Hormones, such as estrogen, thyroid hormone and insulin, 
modulate this process. During aging, and mRNA 
increased LDLr, with decreasing exposure to cholesterol 
contributes to hypercholesterolemia and cardiovascular 
disorders11. 
When the human body is subjected to a diet high in 
cholesterol, serum and liver cholesterol concentration 
increases and lipoproteins (VLDL and LDL) 
concentration increases too, which is considered a 
cardiovascular risk factor12. Several studies have shown 
that the high cholesterol concentration in serum and liver, 
such as triglyceride, from diets rich in cholesterol, have a 
direct relationship between the amount administered and 
the period of the diet. However, some authors report an 
opposite effect on serum triglyceride levels. Hu y col, 
found that a 1% cholesterol diet in rats show a decrease of 
more than 50% of the serum triglyceride levels, but 
increases the hepatic levels of them, also the serum and 
liver figures of the molecule are maintained13. Other 
studies made, in laboratory animals, have tried also to 
establish the metabolic behavior of these diets: rats fed 
high cholesterol diets have an increment in serum and 
hepatic cholesterol concentration14. Rats show an 
increment in serum and hepatic triglyceride levels, which 
conditions a non-alcoholic liver disease (NAFLD).Given 
this evidence, it can be established a relationship between 
dietary cholesterol and triglyceride metabolism, which is 
evident mainly in the liver tissue. However, lipid 
homeostasis in vertebrates is mainly regulated by a family 
of membrane-bound transcription factors known as sterol 
regulatory element binding proteins (SREBP)15. 
 
2.1 Sterol regulatory element binding proteins 
The SREBP are transcription factors with three regions: i) 
A N-terminal fragment, which is actually a family 
b/HLH/LZ (basic/helix-loop-helix/leucine zipper) 
transcription factor with a tyrosine residue in the basic 
region of the b/HLH motive that allows it to join to the 
SRE sequences of the erythrocyte membrane; ii) a central 
domain containing two transmembrane regions separated 
by 31 amino acids located in the endoplasmic reticulum; 
and (iii) a regulatory carboxyterminal domain. SREBP 
has 3 isoforms: SREBP-1a and 1c and SREBP-2. These 
proteins regulate the expression of over 30 genes involved 
in the metabolism and intake of cholesterol, fatty acids, 
triglycerides and phospholipids and in the reduced 
nicotinanide adeninedinucleotide (NADPH) metabolism, 
which is required for the synthesis of these molecules15,16. 
The SREBP-1 and SREBP-2 proteins share 47% 
homology. The SREBP-1a and 1c transcripts are 
produced to be used as an alternative start site of 
transcription and differ in the first exon (exon 1a and 1c). 
SREBP-1a is a more potent transcriptional activator that 
SREBP-1c due to its NH2-terminal higher transactivation 
domain. However, SREBP-1c isoform is predominantly 
expressed in most human and mice tissues, with high 
levels particularly in the liver, white adipose tissue, 
skeletal muscle, adrenal glands and brain. In contrast 
SREBP-1a is highly expressed in cell lines and tissues 
with high capacity for cell proliferation, such as the 
spleen and intestine17,18.SREBP-1a is considered a potent 
activator of all SREBP-responsive genes, including those 
that mediate the cholesterol, fatty acids and triglycerides 
synthesis. SREBP1c preferentially power the genes 
required forfatty acids synthesis and SREBP-2 has a large 
transcription domain has, but it preferentially activates 
cholesterol synthesis (Fig. 1)19,20. 
At cellular level, to monitor the sterols level in the 
erythrocyte membrane, the cell uses two proteins: The 
SREBP cut activating enzyme (SCAP) and the HMG-
CoAR. These proteins share an intramembranal sequence 
called Sterol Screening Domain (SSD). Through this 
domain, sterols cause that SCAP and HMG-CoAR bind to  
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Fig.1: Genes regulated by SERBP and the metabolic intermediates in the pathways for the synthesis of cholesterol, fatty 
 
amembrane protein of the erythrocyte, which is an insulin 
inductor (INSIG). The INSIG protein produces a 
crossroad between the transcriptional and post
transcriptional regulatory mechanisms that ensure 
cholesterol metabolism10. In presence of this molecule, 
the SREBP are retained in the erythrocyte; in its absence 
they are released by proteolysis that allows the activation 
of target genes that control lipid metabolism
Molecularly it occurs as follows: after the translation of
the mRNA, SREBP precursors are retained in the 
erythrocyte membrane through an association with the 
SCAP. Under low cholesterol conditions, the SCAP 
accompanies the SREBP precursors from the erythrocyte 
to the Golgi apparatus where two functionally differ
proteases, site 1 of protease (S1P) and site 2 of protease 
(S2P), hydrolyzed sequentially the precursor protein 
releasing nuclear SREBP (nSREBP) in the cytoplasm
In contrast, when cells have abundant cholesterol SCAP 
binds to INSING, stabilizing the protein and allowing the 
accumulation of a stable complex INSIG/SCAP/SREBP. 
In consequence, the content of SREBP and INSING 
decrease, serving as a reservoir for SREBP. When cells 
are lacking cholesterol, SCAP/SREBP of INSING 
dissociates and then it is degraded in proteasomes. The 
free SCAP/SREBP complex binds proteins from the 
rough endoplasmic reticulum and migrates to the Golgi 
apparatus where SREBP is processed into nSREBP. This 
activates the transactivation genes of the cholesterol 
biosynthetic enzymes and LDLR. At the same time, 
nSREBP activates genes for INSING, for this reason it 
relates to the carbohydrates metabolism15,10
There are three factors that selectively regulate 
SREBP-1c transcription: the liver X activated receptor 
(LXR), insulin and glucagon. Studies in animals fed with 
a high cholesterol diet and the use of oxysterols
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convert palmitate into stearate (C18:0);the stearoyl CoA 
desaturase, which converts stearate intooleate (C18:1) and 
the glycerol 3-phosphate acyltransferase, enzyme that 
participates in the synthesis of phospholipids and 
triglycerides. Also, SREBP-1c and SREBP-2 activate 
three genes: the malic enzyme (ME) gene, glucose 6 
phosphate dehydrogenase (G6PD) gene and 6-
phosphogluconate dehydrogenase gene, required to 
generate NADPH, which is consumed throughout the 
lipids biosynthetic pathway19,16. Malic enzyme presents in 
cytosolic (ME1) and mitochondrial (ME2) form. The 
ME1 catalyzes reversibly the oxidative decarboxylation 
of malate to pyruvate, carbon dioxide and NADPH, and 
then contributes to the de novo synthesis of fatty acids via 
FAS. It has been found that mutations in ME eliminate 
the function of this gene to generate a predisposition to 
obesity and diabetes type 225. 
The SREBP-1c total amount in liver and adipose tissue is 
reduced during fasting, by decreasing insulin levels and 
increasing glucagon levels. This relationship is reversed 
during feeding25. SREBP-1c overexpression in the liver of 
transgenic mice produces a rich in triglycerides fatty liver 
without increasing cholesterol, whereas SREBP-2 over 
expression in transgenic mice results in a 28% increment 
in cholesterol synthesis. In rat hepatocytes, insulin 
treatments increase the total amount of SREBP-1c14. 
SREBP-1a over expression in mouse liver markedly 
increases the expression of genes involved in cholesterol 
synthesis (such as HMGCoA, HMGCoAR, 
squalenesynthetase) and fatty acid synthesis (such as 
ACC, and FAS) causing the accumulation of such 
molecules10. Studies in rats using orotic acid, a compound 
known for the ability to produce nonalcoholic fatty liver 
disease (NAFDL) showed an increment in de novo 
lipogenesis from elevated FAS, ME and G6PDH activity 
in rat liver26. Other studies shown that the activity of FAS, 
G6PDH and MEin the liver is increased in presence of 
hepatic steatosis27. Even Tang y col, established that 
inhibition of the SREBP pathway can be used as a 
therapeutic strategy for treating diseases of lipid 
metabolism including type II diabetes and 
atherosclerosis28. 
As it was mentioned before, cholesterol metabolism is 
under strict genetic regulation and different routes are 
used for absorption, synthesis and secretion. Knowing the 
metabolic pathways activated during the intake of high 
cholesterol diets opens strategies that could potentially 
counteract the effects caused by this type of food.Another 
protein called Peroxisome Proliferation Activated 
Receptor (PPAR) is also involved in the regulation 
expressed in hepatocytes and cardiomyocytes. This 
protein is required for the fatty acids to express its 
function in the genetic processes and participates in a 
large network of genes that regulate the metabolism of 
lipids and glucose, and the differentiation of adipocytes. 
There are several types of PPAR: α, β and γ. PPAR α is 
associated with fatty acid metabolism in the liver, kidney, 
heart, skeletal muscle and brown adipose tissue. PPAR γ 
is associated more with other adipose tissue. Some 
medications such as fibrates and thiazolidinediones act by 
activation of PPAR. The effects of these receptors in 
metabolism range from peroxisomal proliferation, 
increment in fatty acid oxidation, reduction in plasma 
triglyceride levels, and improvement in glucose tolerance. 
It is important to remember that the fatty acids are energy 
elements of the body, and they modulate its metabolism, 
synthesis and oxidation through an allosteric enzyme 
action. In this way, omega fatty acids regulate lipogenic, 
mitochondrial oxidative and gluconeogenic enzymes. 
Long chain polyunsaturated fatty acids reduce hepatic 
lipogenesis and consequently reduce the amount of 
enzymes involved in lipid synthesis; they also modulate 
adipogenesis29. Another regulatory mechanism that refers 
to triglycerides adipose tissue is the storage of a wide 
range of fatty acids, which differ in their molecular 
structure. The output of fatty acids from adipose tissue of 
a subject is selective; it dependson the size of the chain 
and the degree of unsaturation. This has been observed in 
vitro in human and animal adipocytes30. 
As remarkable progress,genes related to the different 
metabolic pathways of lipids provide insight into the 
effects and responses to various diets, which generates 
changes in health from the nutritional status of the 
individual31. Therefore, there will be a beneficial effect to 
consume diets that include functional foods and their 
bioactive components. 
III. FUNCTIONAL FOODS 
Functional foods are defined as specific food substances 
that promote health as part of a varied diet. In general, 
they provide beneficial effects in contributing to the 
maintenance of health status and reducing the risk of 
illness. They are natural or processed foods that, in 
addition to its nutritional components, contain additional 
components, nutritious or not, to help maintain or 
improve health and promote physical fitness and mental 
state of the person who consumes them. There are 
flavonoids that neutralize free radicals focusing on lower 
the risk to develop cancer; caroteniodes that contribute to 
eye health; fiber that reduces the risk of colon cancer and 
various bioactive peptides with antioxidant, antimicrobial 
and antihypertensive effects, among others. Some of the 
components forming part of functional food are shown in 
TABLE 1. However, there are specific components such 
as hypocholesterolemic unsaturated fatty acids and 
bioactive peptides capable of reducing the levels of 
triglycerides and cholesterol32, 33, 34. 
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Table.1: Chemical components with functional potential present in many foods33, 34. 
Component Food Potentialbenefit 
Flavonoids(Catechins and 
flavonols) Green tea and citrus Neutralize free radicals and reduce risk of cancer 
Carotenoids(β-carotene and 
lutein) 
Carrots and green 
vegetables Improvevision 
Fiber Shell grains Reduces the risk of colon cancer 
Unsaturated fatty acids(ω-3 y 
ω-6) 
Fish oils and some 
grasses Reduce levels of cholesterol and triglyceride 
Bioactive peptides 
(antioxidants, ACE inhibitors, 
hypocholesterolemic) 
Eggs, meat, chickpea, 
soy, milk, rice, 
sunflower, and others. 
Reduce the risk of cardiovascular disease and degenerative 
3.1 Unsaturated fatty acid 
Among ordinaryfats and oils, waxes and related 
compounds found in foods and in the human body are 
included. These lipids are composed of triglycerides 
containing a glycerol molecule (an alcohol) and three 
fatty acids. From the chemical standpoint, fatty acids are 
hydrocarbon straight chains terminating in a carboxyl 
group at one end and a methyl group at the other. The 
most common way to classify them is: a) For their degree 
of saturation, they are divided into saturated and 
unsaturated. Aldo,may be classified in monounsaturated 
and polyunsaturated. b) For their length of the chain they 
can be classified as short (4-6 carbons), medium (8-12 
carbons), long (14-18 carbons) or very long (20 or more 
carbons) chain.According to the position of the first 
double bond in the chain, called omega, counting from the 
methyl end, there are three families of polyunsaturated 
fatty acids: ω-3, ω-6 and ω-9. Some are classified as 
essential because the human body cannot synthesize them 
and they are needed for vital functions, these are the ω-3 
and ω-6 families commonly known as omega 3 and 
omega 635,36. 
Unsaturated fatty acids have antithrombotic and 
antiarrhythmic effects, increase bleeding time preventing 
the adhesion of platelets in the arteries, prevent 
atherosclerosis by lowering cholesterol levels in plasma, 
they are useful in hypertensive patients, because they help 
to lower blood pressure and reduce the concentration of 
plasma triglyceride, and they decrease the total 
cholesterol and VLDL37.In the nervous system, 
unsaturated fatty acids are necessary for proper 
development and functioning of the brain and nervous 
system. They are concentrated in the retina and cerebral 
cortex, and have the ability to correct visual and brain 
problems in patients with deficiencies38.Unsaturated fatty 
are hormonal precursors compounds also, such as 
prostaglandins and thromboxanes, which facilitate the 
transmission of messages in the central nervous system37. 
Unsaturated fatty are precursors of other fatty acids such 
as arachidonic, eicosapentaenoic (EPA) and 
docosahexaenoic acid (DHA). DHA is part of the 
membranes of retinal photoreceptors38. 
It is also important to remember that all cell membranes 
contain lipid bilayers and are impermeable to charged 
molecules, for communication between cellsand 
compartments, which require from protein transporters or 
receptors that are embedded in this double layer, occur. 
Furthermore, a flow mechanism that causes the lateral 
movement of proteins and invagination, that allows 
endocytosis and exocytosis, is observed. This fluidity 
requires long chain unsaturatedfatty acids, because 
saturated fatty acids decrease this vital characteristic, 
even more when proteins have to collide with other 
molecules in various biochemical processes. For example, 
the role of insulin to communicate its signal during 
glucose metabolism in rats is damaged when food 
provides more than 10% of dietary calories from saturated 
fatty acids, which can be improved with the intake of 
omega-3 fatty acids39. 
It has been shown that the antiarrhythmic effect of omega 
fatty acids may be associated with functional balance 
between the vague and sympathetic systems whose 
modulation is involved with the cardiac response40. In 
particular EPA and DHA could compare its effect with 
some medications used in the treatment of these cardiac 
problems, which has been observed when fish oil is 
supplied to rats in treatment, due to adrenoceptor involved 
in arrhythmias. These receptors are membrane proteins 
that transmit the catecholamines neuroendocrine message 
in the pace and strength of cardiac contraction. In this 
processDHA hasa similar activity to the one presented by 
theβ-blocking molecules. In relation to atherosclerosis, it 
is the product of a long period of artery inflammation and 
endothelial dysfunction plays an important role on it, 
because the flow associated with this function is mediated 
by nitric oxide and aggravated by atheroma. Omega fatty 
acids provide more fluidity to membranes of endothelial 
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cells promoting the synthesis or output of nitric oxide. To 
prevent atheroma, it is suggested the intake of omega 
fatty acids from fish sources. It has been observed in 
neutrophils and monocytes that fish oil reduces the 
formation of oxygen-derived free radicals and increased 
nitric oxide production in cultured human endothelial 
cells, which is beneficial to avoid atheromas41. As it has 
been already mentioned, another factor associated with 
heart problems is the concentration of HDL-cholesterol 
that may be a predictive factor to avoid the risk of 
coronary heart disease. Although, the current 
recommendations for the treatment of dyslipidemia do not 
include specific HDL-cholesterol values, the acceptable 
range was 35 mg/dL and it has been modified to 40 
mg/dL. Statins, which are 3-hydroxy-3-methyl-CoA 
reductaseinhibitory molecules, are drugs used for 
reducing cholesterol and increase the HDL at moderate 
levels.Other resources for this purpose are, omega fatty 
acids, which are obtained from the oil of various animals 
and plants42.Vegetable fats and oils are usually obtained 
from seeds or the outer layer of the fruit. The percentage 
of this oil reserves widely vary from about 5% in cereals 
to 68% in coconut. In plants and therefore in vegetable 
oils, factors such as the type of crop, agricultural land and 
climatic conditions have a strong influence on the content 
of fatty acids. Mediterranean populations consume large 
quantities of olive oil (rich in oleic acid, which helps in 
the formation of ω-9 acids), vegetables and fish; it was 
found that consumption of fish and olive oil over the life 
of these populations might provide independent protective 
effect on the development of many diseases43. Currently, 
there is interest in the oil obtained from Chia seed (Salvia 
hispanica), due to its high content of unsaturated fatty 
acids44. 
3.2. Bioactive peptides 
Currently the study of dietary proteins as functional 
andbeneficial components has received much attention 
because the generation of bioactive peptides is under 
investigation45. The term bioactive is used to describe 
components with various types of biological activity, such 
as antimicrobial, immunomodulatory, regulating intestinal 
transit, antioxidants, ACE inhibitory, 
hypocholesterolemic and antithrombotic. Bioactive 
peptides are defined as amino acid sequences of between 
2 and 20 residues withoutactivity in the original protein 
and presenting biological activity when released by 
hydrolysis. They cross the intestinal epithelium and reach 
peripheral tissues via systemic circulation, exerting 
specific functions locally, gastrointestinal and systemic46. 
These peptides may alter cellular metabolism and present 
these functions. Its activity is similar to a hormone or 
drug that modulates a physiological role through its 
interaction with a specific receptor triggering a 
physiological response47. Typically, the bioactive peptides 
are hydrophobic and absorbed between 70 and 80% faster 
compared to free amino acids48. 
The method for obtaining these molecules is by the 
hydrolysis of proteins; this is accomplished by chemical 
processes (acids or bases) or by biological processes 
(using enzymes). Biological processes are the most 
recommended if the products will be used in the food 
field49.According to Guadix y col, the proteases or 
proteolytic enzymes are commercial grade enzyme 
mixtures, liquid or solid and are classified in various 
ways50 (TABLE 2). 
However, it should be considered the temperature, pH, 
hydrolysis time and degree of hydrolysis (DH) to obtain 
hydrolyzed with specific characteristics, such as the 
proper distribution of molecular masses of the peptides 
formed, the amino acids released, and the amount of 
residual undigested protein45. The temperature is selected 
to optimize the kinetics of the enzyme or mixture of them, 
using a range from 32 to 50 ºC. The pH is determined 
according to the range where the enzyme activity is at its 
highest. The hydrolysis time is related in direct proportion 
with the DH51. This is a measure of the proteins 
hydrolytic degradation ability. It is defined as the 
percentage of broken peptide bonds in relation to the total 
of them in the original protein. DH is considered practical 
and convenient to control the hydrolytic processes and as 
the largest indicator used for the comparison of different 
protein hydrolysates52. In response to DH, 
hydrolysatescan be classified as: a) Limited hydrolysates 
(DH <10%). They are used to improve the functional and 
technological properties, because an increase in solubility 
occurs. It also improves the emulsifying power, foaming 
and absorption of water or oil, which can be used in 
baked goods and mayonnaise33. b) Extensive hydrolysates 
(DH ≥ 10%). Used in specialized feeding, either as a 
protein supplement or medical diets. These hydrolysates 
include the ones that seek to exploit or improve the 
nutritional characteristics of the protein source, because 
the peptides obtained have higher thermal stability and 
reduced allergenicity. Its size can be more effectively 
absorbed in the gastrointestinal tract as compared to the 
intact proteins. Its high solubility allows their use in 
liquid foods33. 
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Table.2: Classification of proteases according to source, action and catalytic site50. 
 
However, it should be considered the temperature, pH, 
hydrolysis time and degree ofhydrolysis (DH) to obtain 
hydrolyzed with specific characteristics, such as the 
proper distribution of molecular masses of the peptides 
formed, the amino acids released, and the amount of 
residual undigested protein45. The temperature is selected 
to optimize the kinetics of the enzyme or mixture of them, 
using a range from 32 to 50 ºC. The pH is determined 
according to the range where the enzyme activity is at its 
highest. The hydrolysis time is related in direct proportion 
with the DH51. This is a measure of the proteins 
hydrolytic degradation ability. It is defined as the 
percentage of broken peptide bonds in relation to the total 
of them in the original protein. DH is considered practical 
and convenient to control the hydrolytic processes and as 
the largest indicator used for the comparison of different 
protein hydrolysates52.In response to DH, hydrolysatescan 
be classified as:a) Limited hydrolysates (DH<10%). They 
are used to improve the functional and technological 
properties, because an increase in solubility occurs. It also 
improves the emulsifying power, foaming and absorption 
of water or oil, which can be used in baked goods and 
mayonnaise33.b) Extensive hydrolysates (DH ≥ 10%). 
Used in specialized feeding,either as a protein supplement 
or medical diets. These hydrolysates include the ones that 
seek to exploit or improve the nutritional characteristics 
of the protein source, because the peptides obtained have 
higher thermal stability and reduced allergenicity. Its size 
can be more effectively absorbed in the gastrointestinal 
tract as compared to the intact proteins. Its high solubility 
allows their use in liquid foods33. 
Regarding the hypocholesterolemic effect, it has been 
reported more incidence of this activity in plant sources 
compared to animals. Specifically, the case of soybeansis 
mentioned, both recommended by the Food and Drug 
Administration (FDA) and the American Heart 
Association (AHA),because by consuming 25 g/day of 
this protein as part of a diet low in saturated fat there is a 
decrease in cholesterol levels. An estimated consumption 
amount of protein decrease lipoprotein LDL up to 8% in 
patients with high cholesterol levels, while it has no 
adverse effects in people with normal cholesterol levels53. 
By reducing serum cholesterol and LDL concentration 
there is a positive effect as the atherogenic index 
(LDL/HDL) decreases in rats, mice and humans54, 55. 
However, when taken orally these proteins are target of 
gastrointestinal proteases, which originate bioactive 
peptides and contribute to the effects mentioned before. It 
has been reported that soy peptides minimize serum 
cholesterol levels compared to the intact protein. 
Compared with casein, these hydrolysates also reduce 
serum cholesterol because the excretion is promoted 
through feces, because it cannot be absorbed. Similarly, it 
decreases the oxidation of LDL and triglyceride levels 
and enhance the vascular activity56.One possible 
explanation for these events is given by the reduced levels 
of hepatic lipogenic enzymes such as G6PDH and 
stimulation of adiponectin, a hormone involved in 
adipocyte differentiation, and insulin and fatty acids 
sensitivity51. Based on these facts, Nagaokay col found 
that cholesterolmicellar solubility was significantly lower 
during the intake compared to hydrolyze soy protein. The 
same result was observed in serum, liver and intestines of 
rats, indicating inhibition of cholesterol absorption due to 
the inability of the micelles to solubilize the molecule57. It 
has also been found thehypocholesterolemic effect in 
glycinin, specifically in theLeu-Pro-Tyr-Pro-
Argpentapeptide, obtained from soy protein, as mentioned 
Classification Diversity Description 
Source 
Animals 
Vegetables 
Bacterial 
Fungal 
They are extracted from animal tissues, plants, bacteria or fungus and 
its metabolites or its metabolites 
Catalyticaction 
Endoprotease Hydrolyze peptide bonds along the protein chain. 
Exopeptidase Hydrolyzed amino terminals (aminopeptidase) orcarboxylterminals (carboxypeptidase). 
Catalyticsite 
Serineproteinase 
Cisteinproteinase 
Metalloproteinase 
Aspartatoproteinase 
Endoprotease able to hydrolyze amino acid linked to specific 
substrates 
Aminopeptidase 
Carboxipeptidase 
Dipeptidase 
Exopeptidase able to hydrolyze amino, carboxyl or both 
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before. This pentapeptide reduced serum cholesterol in 
mice when administered orally in doses of 50 mg/kg and 
has a homologous enterostatin (Val-Pro-Asp-Pro-Arg) 
structure58. It has been shown that sunflower hydrolysates 
generated when using pepsin or alcalaseproteases and 
undergo to intestinal digestion in vitro, inhibit cholesterol 
incorporation into the micellar suspensions of bile salts. A 
similar effect was obtained with rice bran hydrolysates, 
which managed to reduce total serum cholesterol and 
increase HDL in male Wistar rats59. 
Concerning triglycerides, Ascencio y col reported that 
consumption of soy protein isolates maintained at a low 
level liver stores of these esters60. It is also reported that 
the isolated protein maintains in a low levelplasma 
triglycerides, increases adiponectin, accelerates lipid 
metabolism and decreases the body fat of obese rats and 
mice61,62. 
 
IV. CONCLUSIONS 
Lipids we eat in the diet are important for the growth and 
development of human beings, both for its energy 
function, and for the supply of essential fatty acids. 
However, consumption of saturated fatty acids is harmful 
to the body, as it promotes the formation of cholesterol 
associated with low-density lipoproteins (LDL) and 
increases the rigidity of cell membranes, compromising 
their biological functions. Therefore, controlled fat intake 
may be beneficial to health, to prevent certain 
cardiovascular diseases. Unsaturated fatty acids protect at 
cardiovascular level, because they modulate serum 
cholesterol levels and reduce susceptibility to oxidation of 
LDL. The ω-3 and ω-6 acids prevent chronic 
inflammation, some carcinogenic processes and 
degenerative diseases, because they are precursors of 
eicosanoids or affect the transcription of some genes 
involved in the development of these diseases. These ω-3 
and ω-6 acids exist in foods such as cold-water fish. But 
their presence has been reported in various vegetables like 
amaranth and olive, although chia has stood outdue to its 
high content of these acids. It is known that plant foods 
provide some metabolites with different biological 
properties, being the hypocholesterolemic activity, due to 
enzyme peptides origin, one that has received attention in 
recent years. When these peptides are ingested as part of 
the diet they have a role in reducing the risk of 
cardiovascular diseases, which have been guaranteed by 
in vitro and in vivo studies. 
However, knowledge of how these ingredients work on 
the body is not sufficiently consolidated. This is due to 
the complexity of the multiple interactions between the 
constituents of the food during the digestive process and 
the impact on the metabolism of the same. The different 
lifestyles, age, health status and dietary habits among 
populations, even within the same society, make it 
difficult to generalize the results of studies and indicate 
that a bioactive ingredient is not necessarily effective for 
all consumers. Therefore, there are still many aspects of 
food/health relationship at different stages of life and to 
individuals in different metabolic situations that require 
research. For this it is necessary to demonstrate the 
biological activity of each specific food, this by 
performing clinical studies and evaluating the potential 
health risks of these functional foods to meet the risk-
benefit balance that their consumption entails for the 
population. 
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